DRUG-seq is becoming a widely used transcriptomics method to study how compounds affect cellular biology at scale. In drug discovery, identifying compounds that produce a biological effect is only the starting point. Understanding how those compounds work, their mechanism of action (MoA), is critical for selecting candidates, reducing risk, and accelerating development timelines.
However, traditional approaches such as target-based assays or imaging-based screening are often limited. They focus on predefined markers, which can overlook broader or unexpected biological responses.
Transcriptomics-based approaches have emerged as a powerful alternative, enabling genome-wide analysis of cellular responses to compound exposure through gene expression profiling. Within this space, Digital RNA with pertUrbation of Genes (DRUG-seq) stands out as a scalable approach specifically designed for high-throughput compound profiling in drug discovery.
At Single Cell Discoveries (SCD), DRUG-seq is implemented as discovery-seq, a streamlined, high-throughput service designed to help researchers move efficiently from discovery to mechanism-of-action (MoA) insights.
What is DRUG-seq?
DRUG-seq is a bulk 3’ RNA sequencing–based method optimized for high-throughput compound screening. It generates gene expression profiles for each treatment condition, enabling direct comparison of how different compounds affect cells. It is compatible with cell lines and organoid models from most animal species.
Unlike conventional RNA-seq workflows, DRUG-seq is designed for scalability, reproducibility, and cost efficiency, making it suitable for screening projects involving hundreds to thousands of samples.
Key advantages include:
- High-throughput screening
Hundreds to thousands of compounds or conditions can be profiled in parallel - Cost-efficient transcriptomics
Early barcoding and sample multiplexing significantly reduce per-sample costs - Unbiased transcriptome readout
Genome-wide analysis captures both expected and unexpected drug effects - Low input requirements (~ 10K cells)
Suitable for limited material, including challenging or valuable samples - Streamlined workflow
Direct cell lysis reduces hands-on time and minimizes sample loss
These features make DRUG-seq a practical solution for both small pilot studies and large screening projects.
Want to explore how DRUG-seq enables high-throughput compound profiling in more detail?
Download this tech note to learn how discovery-seq supports scalable transcriptomics in drug discovery.
How does DRUG-seq Work?
DRUG-seq combines an efficient experimental design with scalable sequencing and advanced data analysis, enabling high-throughput compound screening in drug discovery, as seen in the figure below.
Experimental workflow:
- Compound treatment
Cells are cultured and exposed to different compounds under defined conditions, in 96- or 384-well plates. - Direct lysis
After washing steps, cells are lysed and processed directly, simplifying the workflow and decreasing material loss. - Library preparation with early barcoding
Each sample is uniquely labeled, allowing pooling of hundreds of samples - Sequencing
Pooled libraries are sequenced to generate gene expression data, using next-generation sequencing (NGS)
Data analysis:
- Generation of gene expression profiles for each condition
- Differential expression analysis to identify drug-induced changes
- Construction of transcriptional signatures
- Similarity and clustering analyses to group compounds by functional effect
From Gene Expression to Mechanism of action
The key output of DRUG-seq is the transcriptional signature, defined as a pattern of gene expression changes induced by a compound.
Compounds with similar MoA tend to produce similar transcriptional signatures. By comparing these patterns across treatments, DRUG-seq enables:
- Mechanism of action inference: Identification of pathways and biological processes affected by each compound
- Compound classification: Grouping of compounds based on functional similarity, independent of structure
- Detection of off-target effects, Identification of unexpected or undesirable responses
- Prioritization of candidates, Selection based on desired biological profiles
At SCD, data analysis is tailored to each research question, enabling the translation of complex datasets into clear, actionable conclusions.
When to Use DRUG-seq?
DRUG-seq enables scalable, functionally informative profiling in drug discovery pipelines, supporting applications across the pharmaceutical, agritech, and cosmetics sectors.
Best suited for:
- Medium- to high-throughput compound screening
- Large-scale mechanism-of-action studies
- Early-stage drug discovery and candidate prioritization
DRUG-seq requires careful experimental design, including appropriate controls. As with other transcriptomics methods, the choice of approach depends on the balance between throughput, resolution, and research goals. SCD supports this decision-making process from the earliest stages of project design.
Looking to better understand compound mechanisms of action in complex models?
Download this tech note to see how transcriptomic profiling supports MoA discovery at scale.
Integration with Other Transcriptomics Approaches
DRUG-seq can be integrated with other transcriptomics technologies to expand biological insight.
- Bulk RNA-seq for in-depth follow-up studies
- Single-cell RNA-seq to resolve cell-type-specific responses
- Spatial transcriptomics to understand how responses vary within tissue context
At SCD, these approaches can be combined within a single project, enabling a smooth transition from high-throughput screening to deeper biological characterization. This integrated strategy is particularly valuable in complex systems such as tumors or heterogeneous tissues, where both functional and contextual insights are required.
How SCD Supports DRUG-seq Projects
At SCD, DRUG-seq is implemented as Discovery-seq. While based on the same principles, Discovery-seq uses linear (in vitro transcription-based) amplification rather than PCR, improving the detection of lowly expressed genes and reducing amplification bias.
DRUG-seq at SCD is offered as a fully supported service, enabling researchers to integrate high-throughput screening and downstream analysis within a single workflow. Each project is designed to generate actionable results that support decision-making in drug discovery.
Support includes:
- Experimental design and planning tailored to specific research goals
- Scalable DRUG-seq workflows optimized for throughput and reproducibility
- End-to-end processing, from sample handling to sequencing
- Advanced data analysis, focused on MoA insights
By combining technical expertise with flexible project design, SCD enables researchers to efficiently generate and interpret high-throughput transcriptomic data.
Conclusion
DRUG-seq provides a scalable approach to directly link transcriptional responses to mechanism-of-action insights. It enables functional characterization of compounds at a scale that traditional methods cannot easily achieve.
As drug discovery increasingly relies on data-driven decision-making, DRUG-seq offers a practical solution for accelerating compound screening and improving candidate selection.
SCD supports DRUG-seq projects from experimental design through data interpretation, helping researchers confidently uncover MoA signatures. You can send us your cell culture plates without worrying about extra kits and reagents, and we will take it from there, adapting to your experimental setup. Get guidance on designing your DRUG-seq study in a quick 30-minute call with our experts!
Information Guide Discovery-seq
Discover our Discovery-seq service
Download our information guide to access an overview of Single Cell Discoveries, explore our Discovery-seq service, learn how to get started, and gain more valuable insights.
